Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002502
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
- Conditions
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT00084695
- Locations
- 🇺🇸
Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 280
- Registration Number
- NCT00002547
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00003195
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma
- Conditions
- First Posted Date
- 2004-05-21
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00003101
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Evanston Northwestern Health Care, Evanston, Illinois, United States
Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia
- First Posted Date
- 2004-05-19
- Last Posted Date
- 2013-10-16
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 43
- Registration Number
- NCT00002961
- Locations
- 🇺🇸
Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States
🇺🇸Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸Children's Mercy Hospital, Kansas City, Missouri, United States
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer
- Conditions
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 280
- Registration Number
- NCT00003972
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
- Conditions
- First Posted Date
- 2004-04-28
- Last Posted Date
- 2014-05-02
- Target Recruit Count
- 36
- Registration Number
- NCT00003960
- Locations
- 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸Center for Cancer Treatment and Research, Columbia, South Carolina, United States
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Drexel University College of Medicine
- Registration Number
- NCT00003619
- Locations
- 🇺🇸
Medical College of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Medical College of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.